A randomized controlled trial examining the impact of a brief attention-based neurobehavioral transdiagnostic intervention on acute fear response

Information

  • Research Project
  • 10291622
  • ApplicationId
    10291622
  • Core Project Number
    R15MH125375
  • Full Project Number
    1R15MH125375-01A1
  • Serial Number
    125375
  • FOA Number
    PAR-19-133
  • Sub Project Id
  • Project Start Date
    8/1/2021 - 4 years ago
  • Project End Date
    7/31/2024 - a year ago
  • Program Officer Name
    BORJA, SUSAN
  • Budget Start Date
    8/1/2021 - 4 years ago
  • Budget End Date
    7/31/2024 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    7/23/2021 - 4 years ago

A randomized controlled trial examining the impact of a brief attention-based neurobehavioral transdiagnostic intervention on acute fear response

Project Summary/Abstract Despite decades of research, current psychological treatments designed to treat a variety of mental illnesses are not effective for all who receive them. Specifically, well-supported treatments for mental illnesses that involve fear (e.g., PTSD, panic) appear to be effective for the majority of individuals, but consistently leave a group of ?treatment non-responders.? One potential explanation for the observed discrepancy in treatment response may be the focus of modern psychotherapies on relieving symptoms specific to categorical diagnoses, rather than mechanisms underlying why the individual is experiencing the symptoms. Recently, fear-based psychological disorders (e.g., PTSD, specific phobia, panic disorder, social anxiety) have been identified as sharing a distinct set of biomarkers, including genetic biomarkers of acute fear (i.e., fear in the moment) and impairments in controlling attention. Neurobehavioral interventions are therefore a promising class of treatments designed to target the biological markers that may be maintaining the symptoms of various psychological disorders. The Attention Training Technique (ATT) is a neurobehavioral intervention that has garnered attention through its demonstrated effectiveness in reducing symptoms across a variety of psychological diagnoses. While grounded in well-established theory, the mechanisms of change in ATT are largely unknown. One proposed mechanism may be that ATT promotes functional connectivity between regions in the brain implicated in top-down executive control over attention (ventromedial prefrontal cortex [vmPFC] and dorsolateral prefrontal cortex [dlPFC]) and bottom-up attention networks (dorsal anterior cingulate cortex [dACC] and amygdala), resulting in increased top-down regulation of potentially problematic bottom-up attentional processes. The same brain regions implicated in both top-down and bottom-up attentional processes have also been associated with fear responding (i.e., startle response) and fear learning (i.e., how quickly one learns that a stimuli is safe or to be feared). Taken together, the research suggests that acute fear responding may be decreased through increased executive control over attention through engagement in ATT. The proposed randomized clinical trial will test whether a self-administered brief neurobiological intervention (ATT) to increase attentional control will decrease acute fear responding, and whether this change is associated with normative dACC functioning, measured by behavioral proxy. It is expected that those who engage in ATT will show greater attentional control efficiency, which will decrease their acute fear response. It is also expected that those who engage in ATT will also show greater dACC functioning, measured by behavioral proxy and will exhibit decreases in their reported fear as their attentional control increases over the course of the intervention. Additionally, it is expected that the intervention (ATT) will indirectly decrease symptoms of categorical fear-based psychological diagnoses through the identified biomarkers (i.e., attentional control, dACC functioning, acute fear response) to decrease reported symptoms.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R15
  • Administering IC
    MH
  • Application Type
    1
  • Direct Cost Amount
    298371
  • Indirect Cost Amount
    127866
  • Total Cost
    426237
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    242
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NIMH:426237\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MESH
  • Study Section Name
    Biobehavioral Mechanisms of Emotion, Stress and Health Study Section
  • Organization Name
    NORTHERN ILLINOIS UNIVERSITY
  • Organization Department
    PSYCHOLOGY
  • Organization DUNS
    001745512
  • Organization City
    DE KALB
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    601152828
  • Organization District
    UNITED STATES